Business Context and Reporting Period
Company: Eliem Therapeutics, Inc. (ELYM)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: Eliem is a biotechnology company focused on developing therapeutics for autoimmune-driven inflammatory diseases. Its lead product candidate is budoprutug (formerly TNT119), an anti-CD19 monoclonal antibody. The company previously focused on neuronal excitability disorders but paused those programs in 2023.
Key Transaction: On June 27, 2024, Eliem completed the acquisition of Tenet Medicines, Inc. (Tenet), a development-stage biotechnology company. This transaction was accounted for as an asset acquisition. Concurrently, Eliem completed a private placement of common stock, raising approximately $120.0 million in gross proceeds.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(54,889) | $(5,220) | $(56,586) | $(27,510) |
| Net Loss Per Share (Basic & Diluted) | $(1.81) | $(0.19) | $(1.95) | $(1.03) |
| Total Operating Expenses | $56,372 | $6,714 | $59,377 | $30,152 |
| Cash and Cash Equivalents (End of Period) | $223,140 | $25,294 | $223,140 | $25,294 |
| Accumulated Deficit | $(212,565) | $(148,370) | $(212,565) | $(148,370) |
Liquidity: As of June 30, 2024, the company held $223.1 million in cash and cash equivalents. Management estimates this is sufficient to fund operations into 2027.
Material Changes vs. Prior Period
- Acquired In-Process Research and Development (IPR&D): The most significant change was a one-time non-cash expense of $51.7 million recorded in Q2 2024 related to the Tenet acquisition. This expense was recognized because the acquired assets had no alternative future use. This drove the total operating expenses for the quarter to $56.4 million, compared to $6.7 million in Q2 2023.
- Research and Development (R&D): Excluding the IPR&D charge, R&D expenses decreased significantly. For the six months ended June 30, 2024, R&D expenses were $2.1 million, down 77.3% from $9.4 million in the prior year period. This reduction is attributed to the pause of the ETX-123 and ETX-155 programs and reduced headcount.
- General and Administrative (G&A): G&A expenses for the six months ended June 30, 2024, were $5.6 million, a 73.1% decrease from $20.7 million in the prior year. The prior year included $14.5 million in restructuring costs which were not present in the current period.
- Capital Structure: The company issued 31.2 million shares in a private placement and 5.6 million shares as consideration for the Tenet acquisition, significantly increasing outstanding shares from 27.7 million (Dec 31, 2023) to 66.8 million (June 30, 2024).
Guidance, Outlook, and Risks
Outlook and Strategy:
- The company plans to submit an Investigational New Drug (IND) application for budoprutug for systemic lupus erythematosus/lupus nephritis (SLE/LN) and immune thrombocytopenia (ITP).
- Phase 2 clinical trials for these indications are planned subject to regulatory clearance.
- Management expects to finalize a high-concentration formulation of budoprutug for potential subcutaneous dosing by the end of 2024.
- Comprehensive data from the Phase 1b trial in membranous nephropathy (MN) is expected in Q4 2024.
Risks and Contingencies:
- Internal Controls: The company identified material weaknesses in its internal control over financial reporting, specifically regarding the control environment and lack of formal accounting policies. Remediation efforts are underway but not yet concluded.
- Capital Needs: Despite the recent funding, the company anticipates incurring substantial losses for the foreseeable future and will need additional financing to fund operations beyond 2027.
- Development Risk: Success is heavily dependent on the regulatory approval and commercialization of budoprutug. Clinical trials are uncertain, and preliminary data may not predict final results.
- Intellectual Property: The company relies on in-licensed patents and has four pending U.S. provisional patent applications for budoprutug. There is no assurance these will result in issued patents.
Investor Verification Checklist
- Acquisition Accounting: Verify the valuation of the $51.7 million IPR&D expense and the terms of the Tenet acquisition, including the $120 million private placement details.
- Cash Runway: Confirm the $223.1 million cash balance and the assumptions used to project sufficiency of funds into 2027.
- Internal Control Remediation: Monitor progress on remediation of the identified material weaknesses in internal controls over financial reporting.
- Clinical Milestones: Track the timeline for the IND submission for SLE/LN and ITP, and the release of full Phase 1b MN data in Q4 2024.
- Patent Status: Review the status of the four pending U.S. provisional patent applications and the terms of the in-licensed agreements with Acelyrin and CRH.